How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Esperion to Report First Quarter 2024 Financial Results on May 7

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024

Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?

Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?

Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference

Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24

Analysts Offer Insights on Healthcare Companies: Esperion (ESPR) and Masimo (MASI)

U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events